a General Surgery, Department of Surgery , University of Alberta, Cross Cancer Institute , Edmonton , AB , Canada.
b Medical Oncology, Department of Oncology , University of Alberta, Cross Cancer Institute , Edmonton , AB , Canada.
Expert Rev Clin Pharmacol. 2017 Sep;10(9):947-956. doi: 10.1080/17512433.2017.1347503. Epub 2017 Jul 5.
Body surface area dosing of chemotherapeutic agents is based on limited scientific data, and often results in unpredictable plasma drug levels. Cross-sectional computed tomography (CT) imaging provides an accurate measurement of lean mass. This review summarizes emerging roles of lean mass in predicting pharmacokinetics and drug toxicities in cancer patients. Areas covered: A concise review of body composition measurement with CT cross-sectional imaging and its relationship to drug pharmacokinetics and toxicities. A comprehensive review of the predictive value of low lean mass (sarcopenia) in dose-limiting toxicities is also included. Expert commentary: Drug dosing in medical oncology faces many challenges, including heterogeneous body composition profiles. The emerging role of sarcopenia in predicting lean mass may provide the tool needed to more accurately dose patients and prevent dose-limiting toxicities.
体表面积给药法是基于有限的科学数据，通常会导致不可预测的血浆药物水平。横截面计算机断层扫描（CT）成像可提供准确的瘦体重测量。本综述总结了瘦体重在预测癌症患者药代动力学和药物毒性方面的新作用。
CT 横截面成像的身体成分测量及其与药物药代动力学和毒性的关系的简明综述。还包括对低瘦体重（恶病质）在剂量限制毒性中的预测价值的综合综述。
肿瘤医学中的药物剂量面临许多挑战，包括异质的身体成分特征。恶病质在预测瘦体重方面的新作用可能提供了更准确地为患者给药和预防剂量限制毒性所需的工具。
